ANATOMY OF A FAILURE TO LAUNCH: BARRIERS TO GENERIC MARKET ENTRY AND THE USE OF COMPETITION LAW AS A REMEDY
Section
Health & Consumers
Event Description
The webinar will be the occasion for the launch of a White Paper entitled “Anatomy of a failure to launch: A review of barriers to generic and biosimilar entry and the use of competition law”.
The discussion will focus on how to make sure that current barriers to generic and biosimilar medicines market entry can be tackled in order to avoid any unnecessary delays to patient access.
The launch of the White Paper aims to inform the current debate around the IP strategy in the context of the broader Pharmaceutical Strategy of the European Commission. Discussions will include how to deal with IP and patent quality, patent linkage, pricing strategies, as well as ways to ensure effective competition in the pharmaceutical market.
Jobs
Health and Environment Alliance
International Center for Future Generations
CLERENS
CropLife International
Europabüro der Metropolregion FrankfurtRheinMain
SIOP Europe
PLAN INTERNATIONAL EUROP
PLAN INTERNATIONAL EUROP
HYDROGEN EUROPE
CLEAN AVIATION JOINT UNDERTAKING
EURACTIV News
- Compromises on the Pharma Package provide balance, say MEPs ahead of ENVI vote [Advocacy Lab Content]
- Bulgaria tries fighting corruption with mobile access to personal health files [Advocacy Lab Content]
- EHDS is not just an agreement; it’s a promise to patients and researchers, says Vandenbroucke [Advocacy Lab Content]
- Reducing regulatory data protection isn’t a successful strategy, says Roche Netherlands GM [Advocacy Lab Content]
- Investigation into Slovak pandemic management tainted by anti-vaxxer leadership [Advocacy Lab Content]